Myeloablative therapy and bone marrow transplantation in Jehovah's Witnesses with malignancies: single center experience

Mazza, Patrizio; Prudenzano, A; Amurri, B; Palazzo, Giulia; Pisapia, Giovanni; Stani, L; Pricolo, Giancarla

doi:10.1038/sj.bmt.1704179

Cited by 21 publications

(16 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, Jehovah's Witnesses did not offer any objection to this autologous variant of stem cell transplantation [64]. There may be some religious, social or cultural groups outside of the German/European focus with relevant convictions regarding ASCT which were undiscovered by the information retrieval and the defined inclusion and exclusion criteria.…”

Section: Resultsmentioning

confidence: 99%

Ethical issues in autologous stem cell transplantation (ASCT) in advanced breast cancer: A systematic literature review

et al. 2011

View full text Add to dashboard Cite

BackgroundAn effectiveness assessment on ASCT in locally advanced and metastatic breast cancer identified serious ethical issues associated with this intervention. Our objective was to systematically review these aspects by means of a literature analysis.MethodsWe chose the reflexive Socratic approach as the review method using Hofmann's question list, conducted a comprehensive literature search in biomedical, psychological and ethics bibliographic databases and screened the resulting hits in a 2-step selection process. Relevant arguments were assembled from the included articles, and were assessed and assigned to the question list. Hofmann's questions were addressed by synthesizing these arguments.ResultsOf the identified 879 documents 102 included arguments related to one or more questions from Hofmann's question list. The most important ethical issues were the implementation of ASCT in clinical practice on the basis of phase-II trials in the 1990s and the publication of falsified data in the first randomized controlled trials (Bezwoda fraud), which caused significant negative effects on recruiting patients for further clinical trials and the doctor-patient relationship. Recent meta-analyses report a marginal effect in prolonging disease-free survival, accompanied by severe harms, including death. ASCT in breast cancer remains a stigmatized technology. Reported health-related-quality-of-life data are often at high risk of bias in favor of the survivors. Furthermore little attention has been paid to those patients who were dying.ConclusionsThe questions were addressed in different degrees of completeness. All arguments were assignable to the questions. The central ethical dimensions of ASCT could be discussed by reviewing the published literature.

show abstract

Section: Resultsmentioning

confidence: 99%

Ethical issues in autologous stem cell transplantation (ASCT) in advanced breast cancer: A systematic literature review

et al. 2011

View full text Add to dashboard Cite

show abstract

“…These include; leukemia, multiple myeloma, lymphoma, breast cancer, sickle cell disease, thalesemia, aplastic anemia, systemic lupus erythematosus, autoimmune thrombocytopenia, progressive systemic sclerosis, rheumatoid arthritis, juvenile idiopathic arthritis, vasculitis, and multiple sclerosis (Walters 1999;Olalla et al 1999;Tyndall and Millikan 1999;Couto-Silva et al 2001;Slavin et al 2001;Burt et al 2003;Cohen 2003;Einsele et al 2003;Mazza et al 2003;Karussis and Slavin 2004). High dose chemoradiotherapy implemented before HSCT is extremely gonadotoxic.…”

Section: Othersmentioning

confidence: 99%

Ovarian tissue cryopreservation: benefits and risks

2005

View full text Add to dashboard Cite

An increasing number of women have been subjected to cytotoxic chemoradiotherapy for various malignant and nonmalignant diseases. Women who face the possibility of premature or imminent ovarian failure caused by cytotoxic therapy may retain their fertility potential with ovarian tissue cryopreservation. Until recently, this technique could only be performed in a few highly specialized institutions. However, with the latest advances in cryobiology, ovarian tissue cryopreservation is rapidly becoming a more widely offered technique by many medical centers around the world. The indications now extend beyond cancer. Even though the risk of re-implanting pre-existing cancer cells is minimal or non-existent for most types of cancer, this risk needs to be ascertained according to the cancer type and disease stage. The objective of this manuscript is to review the indications, risks and benefits of ovarian tissue cryopreservation.

show abstract

“…121 Zenz et al reported a successful reduced-intensity conditioning transplant in a patient with CML. The degree and nature of transfusion support that is acceptable may vary from patient to patient, and the transplant physicians should initiate a careful discussion with the patient, family, religious advisors, blood bank, and hospital ethics and legal personnel prior to undertaking HSCT.…”

Section: Hsct Patients Who Refuse Blood Transfusionmentioning

confidence: 99%